

# Q4 & FY19 Financial results

"We are very proud of our accomplishments in fiscal year 2019. Our performance this year demonstrates our ability to overcome multiple headwinds and deliver on our financial and operational goals. We enter fiscal 2020 with continued optimism. There are significant opportunities ahead to leverage the capabilities we've built to better serve our customers and their patients around the world. It has been a privilege to lead BD and our global team of talented associates. I'm confident that under Tom Polen's leadership the company will further accelerate its impact as BD enters its next phase of value creation."

—Vince Forlenza, Chairman and CEO



## Revenue performance



Q4 **\$4.6B**

**+6.2%**<sup>1</sup>

FY19 **\$17.3B**

**+5.1%**<sup>1</sup>

## Adjusted EPS



Q4 **\$3.31**

**+12.3%**<sup>2</sup>

FY19 **\$11.68**

**+11.9%**<sup>2</sup>

## Revenue performance by segment<sup>1</sup>



**BD Medical**

Q4 **+5.3%**

FY19 **+5.1%**



**BD Interventional**

Q4 **+7.7%**

FY19 **+5.5%**



**BD Life Sciences**

Q4 **+6.9%**

FY19 **+4.9%**

## Fiscal 2020 guidance



Revenue<sup>1</sup>

**+5.0% to +5.5%**



Adjusted EPS<sup>2</sup>

**\$12.50 to \$12.65**

1. Reflects growth on a currency neutral basis, adjusted to exclude divestitures and other items, as applicable.

2. Adjusted earnings per share growth rate is presented on a currency neutral basis. Adjusted diluted earnings per share results exclude, among other things, the impact of purchase accounting adjustments (including the non-cash amortization of acquisition-related intangible assets); integration, and restructuring and transaction costs.

These materials include non-GAAP financial measures. Reconciliations to the comparable GAAP measures can be found in our fourth quarter earnings release and the financial schedules attached thereto, furnished as an exhibit to the 8-K that BD filed today with the SEC.

This document contains forward-looking statements and it's possible that actual results could differ from our expectations. Factors that could cause such differences appear in our fourth quarter earnings release and in our recent SEC filings.

